IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 0.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 102,492 shares of the company's stock after selling 889 shares during the quarter. Riverbridge Partners LLC owned approximately 0.13% of IDEXX Laboratories worth $43,041,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Alberta Investment Management Corp increased its holdings in shares of IDEXX Laboratories by 25.3% in the fourth quarter. Alberta Investment Management Corp now owns 10,900 shares of the company's stock valued at $4,506,000 after purchasing an additional 2,200 shares during the last quarter. Sagespring Wealth Partners LLC purchased a new stake in IDEXX Laboratories in the 1st quarter valued at $229,000. Banque Transatlantique SA acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $2,681,000. Flossbach Von Storch SE raised its holdings in shares of IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after acquiring an additional 464,791 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of IDEXX Laboratories by 9.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,436 shares of the company's stock valued at $1,007,000 after acquiring an additional 218 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Morgan Stanley raised their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Leerink Partners upped their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, June 11th. Finally, Stifel Nicolaus raised their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $546.00.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,046 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total transaction of $537,372.04. Following the completion of the transaction, the director now owns 262 shares in the company, valued at $134,599.88. The trade was a 79.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 0.8%

Shares of IDXX stock traded up $4.07 during trading on Friday, reaching $523.92. The company's stock had a trading volume of 1,052,498 shares, compared to its average volume of 650,255. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.73. The stock's 50-day moving average price is $486.81 and its 200 day moving average price is $447.64. The company has a market capitalization of $42.13 billion, a price-to-earnings ratio of 48.42, a P/E/G ratio of 3.80 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the business posted $2.71 earnings per share. IDEXX Laboratories's revenue was up 3.6% compared to the same quarter last year. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.